{'fraction_non_alphanumeric': 0.03993203058623619, 'fraction_numerical': 0.03313508920985556, 'mean_word_length': 5.072164948453608, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
TOLERANCE TO THE CARDIOVASCULAR EFFECTS OF Δ9‐TETRAHYDROCANNABINOL IN THE RAT

1 Daily intraperitoneal injections of Δ9‐tetrahydrocannabinol (Δ9‐THC, 10 mg/kg) resulted in tolerance to the effects of the cannabinoid on body weight and body temperature within 1–2 weeks of treatment. 2 Tolerance failed to develop to the suppression of spontaneous motor activity produced by Δ9‐THC during 28 days of treatment with the cannabinoid (10 mg/kg, i.p. per day). 3 Following treatment with vehicle for 28 days, intravenous administration of Δ9‐THC in anaesthetized rats produced a transient pressor response followed by a sustained hypotension and bradycardia. 4 Tolerance to the hypotensive and negative chronotropic responses to intravenous Δ9‐THC was readily apparent in animals which had received daily intraperitoneal injections of Δ9‐THC (10 mg/kg) for 28 days. 5 Tolerance failed to develop to the pressor actions of intravenous Δ9‐THC after 28 days of pretreatment. 6 There was no difference in the pressor response to intravenous noradrenaline in vehicle‐treated animals (1.0 ml/kg, i.p., per day for 28 days) and Δ9‐THC‐treated animals (10 mg/kg, i.p., per day for 28 days).